Track market-moving stories before they get noisy

Key Takeaways MDU reported Q1 2026 EPS of 39 cents, missing estimates and falling 25% year over year. MDU revenues fell 12.76% year over year to $606 million, below consensus expectations. MDU expects 2026 EPS of 93 cents-$1 and plans $565 million in capital spending this year. MDU Resources Group Inc. (MDU - Free Report) reported first-quarter 2026 operating earnings per share (EPS) of 39 cents, which missed the Zacks Consensus Estimate of 42 cents by 7.14%. The bottom line decreased 25% year over year.

Total Revenues of MDUOperating revenues of $606 million missed the Zacks Consensus Estimate of $702 billion by around 13.68%. The top line decreased 12.76% from $ 674.8 million recorded in the year-ago quarter.

Highlights of MDU’s Earnings ReleaseTotal operating expenses were nearly $490.3 million, down 14.3% from the year-ago quarter’s $562 million. The decline was primarily due to lower purchased natural gas sales and a decrease in taxes other than income taxes.

Operating income totaled $115.7 million, up 2.57% from the year-ago quarter’s $112.8 million.

Interest expenses were $32.7 million, up 22.1% year over year.

Financial Highlights of MDUAs of March 31, 2026, cash and cash equivalents were $53.3 million compared with $28.2 million as of Dec. 31, 2025.
Long-term debt as of March 31, 2026, was $2.38 billion compared with $2.53 billion as of Sept. 30, 2025.

In the first three months of 2026, net cash provided by operating activities was $149.2 million compared with $217.5 million in the year-ago period.

In the first three months of 2026, capital expenditure was $92.4 million compared with $93 million in the year-ago period.

MDU’s GuidanceFor 2026, MDU Resources expects its earnings to be between 93 cents and $1 per share. The Zacks Consensus Estimate is pegged at 98 cents, which lies at the higher end of the company’s projected range.

The company continues to expect a long-term EPS growth rate of 6-8%.

MDU anticipates its utility customers’ growth to continue at an annual rate of 1-2%.

Capital expenditure for 2026 is projected at $565 million and plans to invest $3,113 million during the 2026-2030 period.

MDU’s Zacks RankMDU Resources currently has a Zacks Rank #4 (Sell).

You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.

Recent ReleasesAtmos Energy (ATO - Free Report) posted second-quarter fiscal 2026 earnings of $3.47 per share, which topped the Zacks Consensus Estimate of $3.37 by 2.97%. The bottom line improved 14.52% from the year-ago quarter’s $3.03.

Total revenues of $1.96 billion missed the Zacks Consensus Estimate of $2.24 billion by 12.37%. However, the top line rose 0.61% from the prior-year quarter’s $1.95 billion.

Southwest Gas Holdings Inc. (SWX - Free Report) reported first-quarter 2026 operating earnings of $1.91 per share, which beat the Zacks Consensus Estimate of $1.88 by 1.60%. The bottom line increased 15.76% from the year-ago quarter.

Operating revenues totaled $585.1 million, which lagged the Zacks Consensus Estimate of $737 million by 20.62%. The top line decreased 21.61% from $746.4 million reported in the prior-year quarter.

Northwest Natural (NWN - Free Report) reported first-quarter 2026 operating earnings of $2.33 per share, which beat the Zacks Consensus Estimate of $2.31 by 0.87%. The bottom line increased 2.19% from the year-ago quarter.

Operating revenues totaled $490 million, which lagged the Zacks Consensus Estimate of $504 million by 2.78%. The top line increased 0.79% from $494 million reported in the prior-year quarter.

, /PRNewswire/ -- The board of directors of MDU Resources Group, Inc. (NYSE: MDU) today declared a quarterly dividend on the company's common stock of 14 cents per share, unchanged from the previous quarter. The board continues to target a long-term dividend payout ratio of 60% to 70% of earnings.

The dividend is payable on July 1, 2026 to stockholders of record as of June 11, 2026.

About MDU Resources Group, Inc.
MDU Resources Group, Inc., a member of the S&P SmallCap 600 index, strives to deliver safe, reliable, affordable and environmentally responsible electric utility and natural gas distribution services to more than 1.2 million customers across the Pacific Northwest and Midwest. In addition to its utility operations, the company's pipeline business operates a more than 3,800-mile natural gas pipeline network and storage system, ensuring reliable energy delivery across the Northern Plains. With a legacy spanning over a century, MDU Resources remains focused on energizing lives for a better tomorrow. For more information about MDU Resources, visit www.mdu.com or contact the investor relations department at [email protected].

Investor Contact: Brent Miller, treasurer, 701-530-1730
Media Contact: Byron Pfordte, director of integrated communications, 208-377-6050

SOURCE MDU Resources Group, Inc.

Today,[url="]Calix, Inc.[/url] (NYSE: CALX) launched enhancements to [url="]Calix Agent Workforce™ Cloud[/url] that help service providers improve campaign m

Information in Investor’s Business Daily is for informational and educational purposes only and should not be construed as an offer, recommendation, solicitation, or rating to buy or sell securities. The information has been obtained from sources we believe to be reliable, but we make no guarantee as to its accuracy, timeliness, or suitability, including with respect to information that appears in closed captioning. Historical investment performances are no indication or guarantee of future success or performance. Authors/presenters may own the stocks they discuss. We make no representations or warranties regarding the advisability of investing in any particular securities or utilizing any specific investment strategies. Information is subject to change without notice. For information on use of our services, please see our Terms of Use.

*Real-time prices by Nasdaq Last Sale. Real-time quote and/or trade prices are not sourced from all markets. Ownership data provided by LSEG and Estimate data provided by FactSet.

IBD, IBD Digital, IBD Live, IBD Weekly, Investor's Business Daily, Leaderboard, MarketDiem, MarketSurge and other marks are trademarks owned by Investor's Business Daily, LLC.

©2026 Investor’s Business Daily, LLC. All Rights Reserved.

Key Takeaways DNLI won FDA accelerated approval for Avlayah, its first drug for Hunter syndrome in nearly 20 years.Avlayah showed 91% reduction in key biomarker CSF HS, with 93% patients reaching normal levels.DNLI's TransportVehicle platform enables brain delivery, with a confirmatory COMPASS study ongoing. Denali Therapeutics, Inc. (DNLI - Free Report) secured a major regulatory win with the FDA approval of lead pipeline candidate tividenofusp alfa-eknm, under the brand name Avlayah, for the treatment of Hunter Syndrome.

The FDA granted accelerated approval to Avlayah, marking the first new treatment option in nearly 20 years for patients with Hunter syndrome, a rare lysosomal storage disorder. It is also the first approved therapy in a new class of biologics designed to cross the blood-brain barrier by targeting the transferrin receptor.

The continued approval for this indication may be contingent upon verification of clinical benefit in a confirmatory trial.

More on DNLI’s First Commercial DrugDeveloped by Denali, Avlayah is enabled by its TransportVehicle platform, which facilitates delivery of biologics throughout the body, including the brain. The approval also comes with a Rare Pediatric Disease Priority Review Voucher.

Hunter syndrome is caused by a deficiency of the iduronate 2-sulfatase enzyme, leading to the buildup of harmful substances in tissues, including the brain, and resulting in progressive cognitive, motor and organ damage.

Avlayah is an enzyme replacement therapy indicated for pediatric patients with Hunter syndrome (MPS II), targeting neurological symptoms when initiated early.

Approval was based on strong biomarker data, showing a 91% reduction in cerebrospinal fluid heparan sulfate levels (CSF HS), a key disease marker.

In a phase I/II study, treatment led to a 91% reduction in CSF HS levels from baseline at 24 weeks (95% CI: 89%–92%). By that time, 93% of patients (41 of 44) achieved CSF HS levels within the normal range.

The ongoing global phase II/III COMPASS study is expected to provide confirmatory data and support regulatory filings worldwide, including in young adult patients with Hunter syndrome.

Positive outcomes from this study could further expand the drug’s commercial potential and reinforce Denali’s position in the rare neurodegenerative disease market.

This milestone represents a major advancement for the Hunter syndrome community, addressing longstanding unmet needs, particularly neurological complications. Avlayah is administered weekly and is expected to become available in the United States shortly, supported by patient access programs from Denali.

What Does This Mean for DNLI?Shares of Denali gained 7.15% on March 25, following the news of FDA approval.  

In the past six months, Denali stock has gained 54.8% compared with the industry’s growth of 11.6%.

Image Source: Zacks Investment Research

The approval marks the company’s first commercial product and a potential inflection point for its long-term growth story.

While the successful commercialization holds the key, the approval of Avlayah underscores the potential of Denali’s TransportVehicle platform to address the longstanding challenge of delivering biologic therapies across the blood-brain barrier, with the goal of transforming treatment for a broad range of neurodegenerative diseases, lysosomal storage disorders and other serious conditions affecting millions worldwide.

DNLI’s Deep Pipeline Also Boosts Growth StudyDenali boasts a deep pipeline. One promising asset is DNL126, being developed for Sanfilippo syndrome type A, a rare pediatric neurodegenerative disorder. DNLI is also evaluating DNL628 (OTV:MAPT) for Alzheimer’s disease.

Strategic partnerships further strengthen Denali’s development capabilities and help mitigate financial and clinical risk.

Denali is developing other candidates in partnership with Takeda (TAK - Free Report) , Biogen (BIIB - Free Report) and Sanofi (SNY - Free Report) .

Denali and Takeda have collaborated to develop DNL593, an investigational therapeutic designed to deliver progranulin across the blood-brain barrier for the treatment of granulin (GRN) mutation-associated frontotemporal dementia (FTD-GRN).
Denali and Biogen continue co-development of BIIB122.

Biogen is leading the global phase IIb LUMA study, evaluating BIIB122's impact on disease progression in early-stage PD. Data is expected in mid-2026.

Denali is conducting the phase IIa BEACON study, specifically enrolling participants with LRRK2-associated PD to assess how LRRK2 inhibition may impact this disease.

In October, Denali submitted an investigational new drug application (IND) for DNL952 (ETV:GAA) to begin clinical studies in Pompe disease. Last month, Denali announced that the FDA has lifted the clinical hold on the investigational new drug (IND) application for DNL952. Phase I study start-up activities are underway.

Sanofi is developing eclitasertib for the treatment of moderate-to-severe ulcerative colitis. Data from the phase II study is expected in the first half of the year.

The company’s sound cash position is a positive and underscores its ability to fund ongoing programs.

Zacks Rank

Posted by Defense World Staff on Apr 5th, 2026

Denali Therapeutics Inc. (NASDAQ:DNLI – Get Free Report) has been given a consensus recommendation of “Moderate Buy” by the sixteen ratings firms that are covering the stock, MarketBeat.com reports. One equities research analyst has rated the stock with a sell recommendation, one has given a hold recommendation, twelve have issued a buy recommendation and two have issued a strong buy recommendation on the company. The average twelve-month price target among analysts that have updated their coverage on the stock in the last year is $34.8182.

DNLI has been the topic of several research reports. The Goldman Sachs Group upped their price objective on Denali Therapeutics from $35.00 to $40.00 and gave the stock a “buy” rating in a report on Thursday, March 26th. Weiss Ratings reissued a “sell (d-)” rating on shares of Denali Therapeutics in a research note on Wednesday, January 21st. Stifel Nicolaus boosted their target price on Denali Therapeutics from $34.00 to $41.00 and gave the stock a “buy” rating in a research report on Thursday, March 26th. BTIG Research upped their price target on Denali Therapeutics from $36.00 to $38.00 and gave the company a “buy” rating in a research note on Wednesday, March 25th. Finally, Jefferies Financial Group reiterated a “buy” rating and issued a $40.00 price target on shares of Denali Therapeutics in a report on Monday, March 2nd.

Read Our Latest Report on Denali Therapeutics

Denali Therapeutics Stock Performance DNLI opened at $20.65 on Friday. Denali Therapeutics has a 1-year low of $10.57 and a 1-year high of $23.77. The stock has a market capitalization of $3.27 billion, a PE ratio of -6.95 and a beta of 1.10. The company has a current ratio of 9.16, a quick ratio of 9.16 and a debt-to-equity ratio of 0.01. The firm has a 50-day moving average price of $20.49 and a two-hundred day moving average price of $18.05.

Denali Therapeutics (NASDAQ:DNLI – Get Free Report) last announced its earnings results on Thursday, February 26th. The company reported ($0.73) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.75) by $0.02. During the same quarter last year, the business earned ($0.67) EPS. As a group, equities analysts anticipate that Denali Therapeutics will post -2.71 earnings per share for the current fiscal year.

Insider Transactions at Denali Therapeutics In other news, insider Alexander O. Schuth sold 17,218 shares of the firm’s stock in a transaction dated Tuesday, January 6th. The shares were sold at an average price of $16.50, for a total value of $284,097.00. Following the transaction, the insider owned 282,828 shares of the company’s stock, valued at approximately $4,666,662. This trade represents a 5.74% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, CEO Ryan J. Watts sold 35,198 shares of Denali Therapeutics stock in a transaction that occurred on Tuesday, January 6th. The stock was sold at an average price of $16.50, for a total transaction of $580,767.00. Following the sale, the chief executive officer owned 296,833 shares of the company’s stock, valued at approximately $4,897,744.50. This represents a 10.60% decrease in their position. The SEC filing for this sale provides additional information. Corporate insiders own 12.50% of the company’s stock.

Institutional Trading of Denali Therapeutics A number of institutional investors have recently bought and sold shares of DNLI. Vanguard Group Inc. boosted its position in shares of Denali Therapeutics by 8.9% in the 4th quarter. Vanguard Group Inc. now owns 13,057,890 shares of the company’s stock worth $215,586,000 after purchasing an additional 1,064,972 shares during the last quarter. Baillie Gifford & Co. increased its holdings in Denali Therapeutics by 6.2% in the fourth quarter. Baillie Gifford & Co. now owns 12,310,889 shares of the company’s stock valued at $203,253,000 after purchasing an additional 719,304 shares during the last quarter. T. Rowe Price Investment Management Inc. lifted its stake in Denali Therapeutics by 28.7% in the fourth quarter. T. Rowe Price Investment Management Inc. now owns 7,254,132 shares of the company’s stock valued at $119,766,000 after buying an additional 1,615,565 shares during the period. Temasek Holdings Private Ltd lifted its stake in Denali Therapeutics by 30.9% in the fourth quarter. Temasek Holdings Private Ltd now owns 7,012,974 shares of the company’s stock valued at $115,784,000 after buying an additional 1,657,142 shares during the period. Finally, State Street Corp boosted its holdings in Denali Therapeutics by 14.6% during the fourth quarter. State Street Corp now owns 6,263,371 shares of the company’s stock worth $103,408,000 after buying an additional 799,110 shares during the last quarter. Institutional investors and hedge funds own 92.92% of the company’s stock.

About Denali Therapeutics (Get Free Report)

Denali Therapeutics is a clinical‐stage biopharmaceutical company focused on developing therapies for neurodegenerative diseases. The company’s research leverages a proprietary Blood–Brain Barrier Transport Vehicle (TV) platform designed to enable large molecules, including antibodies and enzymes, to penetrate the central nervous system. Denali’s approach includes small molecules, monoclonal antibodies and gene therapy candidates aimed at key drivers of disorders such as Alzheimer’s disease, Parkinson’s disease, amyotrophic lateral sclerosis (ALS) and frontotemporal dementia.

Among Denali’s lead programs is an orally delivered leucine‐rich repeat kinase 2 (LRRK2) inhibitor for Parkinson’s disease, and an anti‐TREM2 antibody designed to modulate microglial activity in Alzheimer’s patients.

See Also Five stocks we like better than Denali Therapeutics

Receive News & Ratings for Denali Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Denali Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

« PREVIOUS HEADLINEDENTSPLY SIRONA Inc. (NASDAQ:XRAY) Given Average Recommendation of “Hold” by Analysts

NEXT HEADLINE »Public Storage (NYSE:PSA) Given Consensus Recommendation of “Hold” by Analysts

Posted by Defense World Staff on Apr 6th, 2026

Capricorn Fund Managers Ltd acquired a new stake in Denali Therapeutics Inc. (NASDAQ:DNLI – Free Report) in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor acquired 62,197 shares of the company’s stock, valued at approximately $1,027,000.

Other institutional investors and hedge funds have also made changes to their positions in the company. Foresite Capital Management VI LLC acquired a new stake in shares of Denali Therapeutics in the third quarter valued at approximately $14,520,000. AlphaQuest LLC boosted its holdings in Denali Therapeutics by 224.1% in the 3rd quarter. AlphaQuest LLC now owns 74,422 shares of the company’s stock valued at $1,081,000 after purchasing an additional 51,458 shares during the last quarter. Aberdeen Group plc grew its stake in shares of Denali Therapeutics by 23.4% in the 3rd quarter. Aberdeen Group plc now owns 1,113,586 shares of the company’s stock valued at $16,169,000 after buying an additional 210,835 shares during the period. Principal Financial Group Inc. increased its holdings in shares of Denali Therapeutics by 18.5% during the 3rd quarter. Principal Financial Group Inc. now owns 1,271,190 shares of the company’s stock worth $18,458,000 after buying an additional 198,207 shares during the last quarter. Finally, Holocene Advisors LP increased its position in shares of Denali Therapeutics by 677.8% during the 3rd quarter. Holocene Advisors LP now owns 3,135,712 shares of the company’s stock worth $45,531,000 after purchasing an additional 2,732,540 shares during the last quarter. 92.92% of the stock is currently owned by institutional investors and hedge funds.

Insiders Place Their Bets In other news, insider Alexander O. Schuth sold 17,218 shares of the business’s stock in a transaction on Tuesday, January 6th. The stock was sold at an average price of $16.50, for a total value of $284,097.00. Following the completion of the transaction, the insider directly owned 282,828 shares of the company’s stock, valued at $4,666,662. The trade was a 5.74% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, CEO Ryan J. Watts sold 35,198 shares of the business’s stock in a transaction that occurred on Tuesday, January 6th. The shares were sold at an average price of $16.50, for a total transaction of $580,767.00. Following the completion of the transaction, the chief executive officer directly owned 296,833 shares of the company’s stock, valued at approximately $4,897,744.50. This represents a 10.60% decrease in their position. The disclosure for this sale is available in the SEC filing. 12.50% of the stock is currently owned by insiders.

Wall Street Analysts Forecast Growth DNLI has been the topic of a number of research analyst reports. BTIG Research boosted their target price on Denali Therapeutics from $36.00 to $38.00 and gave the company a “buy” rating in a research report on Wednesday, March 25th. Robert W. Baird lifted their price objective on Denali Therapeutics from $29.00 to $32.00 and gave the company an “outperform” rating in a research note on Thursday, March 26th. Wedbush dropped their price objective on Denali Therapeutics from $31.00 to $30.00 and set an “outperform” rating on the stock in a report on Thursday, December 11th. Morgan Stanley boosted their target price on Denali Therapeutics from $40.00 to $42.00 and gave the company an “overweight” rating in a report on Thursday, March 26th. Finally, Stifel Nicolaus raised their price target on Denali Therapeutics from $34.00 to $41.00 and gave the stock a “buy” rating in a report on Thursday, March 26th. Two equities research analysts have rated the stock with a Strong Buy rating, twelve have assigned a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average price target of $34.82.

Check Out Our Latest Analysis on DNLI

Denali Therapeutics Stock Performance Shares of DNLI stock opened at $20.65 on Monday. The company has a current ratio of 9.16, a quick ratio of 9.16 and a debt-to-equity ratio of 0.01. The stock has a 50 day simple moving average of $20.49 and a 200-day simple moving average of $18.08. The company has a market cap of $3.27 billion, a price-to-earnings ratio of -6.95 and a beta of 1.10. Denali Therapeutics Inc. has a 12-month low of $10.57 and a 12-month high of $23.77.

Denali Therapeutics (NASDAQ:DNLI – Get Free Report) last posted its quarterly earnings results on Thursday, February 26th. The company reported ($0.73) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.75) by $0.02. During the same period in the previous year, the company earned ($0.67) earnings per share. On average, equities analysts forecast that Denali Therapeutics Inc. will post -2.71 EPS for the current year.

Denali Therapeutics Profile (Free Report)

Denali Therapeutics is a clinical‐stage biopharmaceutical company focused on developing therapies for neurodegenerative diseases. The company’s research leverages a proprietary Blood–Brain Barrier Transport Vehicle (TV) platform designed to enable large molecules, including antibodies and enzymes, to penetrate the central nervous system. Denali’s approach includes small molecules, monoclonal antibodies and gene therapy candidates aimed at key drivers of disorders such as Alzheimer’s disease, Parkinson’s disease, amyotrophic lateral sclerosis (ALS) and frontotemporal dementia.

Among Denali’s lead programs is an orally delivered leucine‐rich repeat kinase 2 (LRRK2) inhibitor for Parkinson’s disease, and an anti‐TREM2 antibody designed to modulate microglial activity in Alzheimer’s patients.

Featured Articles Five stocks we like better than Denali Therapeutics

Receive News & Ratings for Denali Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Denali Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

« PREVIOUS HEADLINESG Americas Securities LLC Purchases 13,884 Shares of Tompkins Financial Corporation $TMP

NEXT HEADLINE »Jackson Financial Inc. $JXN Stock Position Lifted by SG Americas Securities LLC

Key Takeaways DNLI stock fell after Takeda ended its DNL593 collaboration, citing strategic priorities, not safety issues. Denali regains full ownership of DNL593 and plans to advance the therapy independently toward 2026 data. DNL593 study shows early biomarker gains; Denali now bears full development and commercialization costs. Shares of Denali Therapeutics Inc. (DNLI - Free Report) were down 6.15% on April 6, after the company announced that partner Takeda (TAK - Free Report) has decided to terminate their collaboration agreement to co-develop and co-commercialize DNL593 (PTV:PGRN) on April 3.

Per DNLI, Takeda’s decision was based on strategic priorities and not on any efficacy or safety issues.

Following the termination of the co-development agreement, Denali will regain full ownership of DNL593 along with its intellectual property.

Denali stock has gained 17.4% year to date compared with the industry’s growth of 0.4%.

Image Source: Zacks Investment Research

More on DNLI’s Frontotemporal Dementia-granulin CandidateDNL593 is an investigational progranulin replacement therapy designed using Denali’s Protein TransportVehicle (PTV) platform to deliver progranulin across the blood-brain barrier for the treatment of frontotemporal dementia caused by GRN mutations (FTD-GRN).

Denali plans to independently advance DNL593 and post phase I/II study results by the end of 2026.

The ongoing phase I/II study of DNL593 has completed enrollment with 40 participants diagnosed with FTD-GRN, with biomarker data expected later in 2026. Earlier interim results from healthy volunteers showed dose-dependent increases in cerebrospinal fluid progranulin levels, indicating effective brain delivery. The therapy has been generally well tolerated so far, with no major safety concerns reported.

Frontotemporal dementia is the most common form of dementia in individuals under 60. It leads to progressive decline in behavior, personality, and language or motor functions. Mutations in the GRN gene, which encodes the progranulin protein, are among the leading genetic causes of the disease. Currently, there are no approved treatments to halt or slow its progression.

Regaining full control of DNL593 is a strategic positive, as it allows Denali to capture all future value if the therapy succeeds.

However, Takeda’s exit may raise concerns. Even though the decision was not tied to safety or efficacy, the loss of a large pharma partner removes external validation and shared financial burden. Denali will now need to fund late-stage development and potential commercialization on its own, increasing capital requirements.

Denali’s Recent Drug Approval: A Major BoostLast month, Denali secured a major regulatory win with the FDA approval of lead pipeline candidate tividenofusp alfa-eknm, under the brand name Avlayah, for the treatment of Hunter Syndrome.

The approval marks the company’s first commercial product and a potential inflection point for its long-term growth story.

The FDA granted accelerated approval to Avlayah, marking the first new treatment option in nearly 20 years for patients with Hunter syndrome, a rare lysosomal storage disorder. It is also the first approved therapy in a new class of biologics designed to cross the blood-brain barrier by targeting the transferrin receptor.

While successful commercialization remains key, the approval of Avlayah underscores the potential of Denali’s TransportVehicle platform to address the longstanding challenge of delivering biologic therapies across the blood-brain barrier, with the goal of transforming treatment for a broad range of neurodegenerative diseases, lysosomal storage disorders, and other serious conditions affecting millions worldwide.

Denali boasts a deep pipeline. One promising asset is DNL126, being developed for Sanfilippo syndrome type A, a rare pediatric neurodegenerative disorder. DNLI is also evaluating DNL628 (OTV:MAPT) for Alzheimer’s disease.

Strategic partnerships further strengthen Denali’s development capabilities and help mitigate financial and clinical risk.

Denali is developing other candidates in partnership with Biogen (BIIB - Free Report) and Sanofi (SNY - Free Report) .

DNLI and Biogen continue co-development of BIIB122.

Biogen is leading the global phase IIb LUMA study, evaluating BIIB122's impact on disease progression in early-stage PD. Data is expected in mid-2026.

Denali is conducting the phase IIa BEACON study, specifically enrolling participants with LRRK2-associated PD, to assess how LRRK2 inhibition may impact this disease.

Sanofi is developing eclitasertib for the treatment of moderate-to-severe ulcerative colitis. Data from the phase II study is expected in the first half of the year.

Another promising asset is DNL126, being developed for Sanfilippo syndrome type A, a rare pediatric neurodegenerative disorder. DNLI is also evaluating DNL628 (OTV:MAPT) for Alzheimer’s disease.

The company’s sound cash position is a positive and underscores its ability to fund ongoing programs.

DNLI's Zacks Rank

Denali Therapeutics has transitioned from a speculative platform to a commercial-stage rare disease company with FDA approval of AVLAYAH for Hunter syndrome. DNLI's TransportVehicle technology enables delivery of biologics across the blood-brain barrier, providing significant differentiation and commercial potential in neurodegenerative and lysosomal storage diseases. With $1.17 billion in pro-forma liquidity and a focused initial launch, DNLI is positioned for 2.8 years of runway, reducing near-term capital risk.

FDA approved AVLAYAH™ (tividenofusp alfa-eknm) for treatment of Hunter syndrome (MPS II) and as first medicine to leverage transferrin receptor to cross blood-brain barrierAVLAYAH launched in U.S. with strong momentum, vibrant community engagement, and first patients treated in commercial setting in AprilBroad clinical pipeline progressing for lysosomal storage and neurodegenerative diseases, including first patient dosed with Oligonucleotide TransportVehicle™ (OTV)-enabled DNL628 (OTV:MAPT) targeting tau for Alzheimer's diseaseAdvancing DNL593 (PTV:PGRN) in Phase 1/2 study for GRN-related frontotemporal dementia after regaining full rights, with data expected by end of 2026 SOUTH SAN FRANCISCO, Calif., May 07, 2026 (GLOBE NEWSWIRE) -- Denali Therapeutics Inc. (Nasdaq: DNLI) today reported financial results for the first quarter ended March 31, 2026, and provided business highlights, including the recent U.S. Food and Drug Administration (FDA) approval of AVLAYAH™ (tividenofusp alfa-eknm).

“The FDA approval of AVLAYAH is a major milestone for Denali, for the Hunter syndrome community, and for the field of biotherapeutics enabled to cross the blood-brain barrier. We are thrilled by the strong engagement with the community, seamless execution by our commercial team, and achievement of our first patient dosed in less than one month from approval,” said Ryan Watts, Ph.D., Chief Executive Officer of Denali Therapeutics. “AVLAYAH provides validation for our TransportVehicle™ (TV) platform enabling our broad clinical portfolio for lysosomal storage and neurodegenerative diseases. We are excited about progress achieved across the portfolio, including dosing of the first patients with our Oligonucleotide TV-enabled investigational therapy DNL628 (OTV:MAPT) targeting tau for Alzheimer’s disease and advancing DNL593 (PTV:PGRN) for FTD-GRN after regaining full rights."

First Quarter 2026 and Recent Program Updates

COMMERCIAL PRODUCT

AVLAYAH (tividenofusp alfa-eknm) for Hunter syndrome (mucopolysaccharidosis type II [MPS II])

On March 25, 2026, Denali announced AVLAYAH (tividenofusp alfa-eknm) received accelerated approval for the treatment of neurologic manifestations of Hunter syndrome (MPS II) when initiated in presymptomatic or symptomatic pediatric patients weighing at least 5 kg prior to advanced neurologic impairment. Continued approval for this indication may be contingent upon verification of clinical benefit in a confirmatory trial. The U.S. commercial launch of AVLAYAH is underway and the first patients have received therapy. All key operational launch components are in place, including availability of commercial product through an established distribution channel and fully operational patient support hub. The major health systems and key national and regional payers have been engaged. The ongoing global Phase 2/3 COMPASS study is designed to generate confirmatory evidence and support global regulatory submissions for AVLAYAH.

CLINICAL PROGRAMS

DNL126 (ETV:SGSH) for Sanfilippo syndrome type A (MPS IIIA)

DNL126 is an investigational, intravenously administered, Enzyme TransportVehicle™ (ETV)-enabled N-sulfoglucosamine sulfohydrolase (SGSH) replacement therapy designed to deliver SGSH into the brain and body, with the goal of addressing the behavioral, cognitive and physical manifestations of Sanfilippo syndrome type A. The Phase 1/2 trial of DNL126 is ongoing, and start-up activities are underway for a global Phase 3 confirmatory study. Denali expects a Biologics License Application (BLA) submission and potential accelerated approval for DNL126 for Sanfilippo syndrome type A in 2027.

DNL593 (PTV:PGRN) for GRN-related frontotemporal dementia (FTD-GRN)

Denali is conducting a Phase 1/2 study of DNL593, an investigational, intravenously administered progranulin replacement therapy utilizing Denali’s Protein TransportVehicle™ (PTV) to deliver progranulin across the blood-brain barrier (BBB) and into the brain for individuals with FTD-GRN. Enrollment in the study is complete with a total of 40 participants with FTD-GRN, and results are expected by the end of 2026.

DNL628 (OTV:MAPT) for Alzheimer's disease

In March 2026, the first patient was dosed in the Phase 1b study of DNL628, which is an investigational therapy for Alzheimer’s disease and enabled by Denali’s Oligonucleotide TransportVehicle™ (OTV). DNL628 is designed to cross the BBB and reduce the tau protein by targeting the MAPT gene that encodes for tau. Denali expects data from this study in 1H 2027.

DNL952 (ETV:GAA) for Pompe disease

DNL952 is enabled by Denali’s ETV and designed to enhance delivery of the missing enzyme, GAA, into muscle tissues and across the BBB into the brain. Phase 1 study start-up activities are underway.

BIIB122/DNL151 (small molecule LRRK2 inhibitor) for Parkinson’s disease

A clinical data readout of the global Phase 2b LUMA study of BIIB122 for early-stage Parkinson’s disease is expected in mid-2026. Denali’s Phase 2a BEACON study in individuals with Parkinson’s disease who are confirmed by genetic testing to be carriers of a pathogenic LRRK2 variant is ongoing. The LRRK2 program is being developed in collaboration with Biogen.

IND-ENABLING STAGE PROGRAMS

Denali has multiple additional programs in the IND-enabling stage including DNL921 (ATV:Abeta) for Alzheimer’s disease; DNL111 (ETV:GCase) for Parkinson’s disease and Gaucher disease; DNL622 (ETV:IDUA) for MPS I; and DNL422 (OTV:SNCA) for Parkinson’s disease. Denali is on track to submit a regulatory filing for DNL921 in the first half of 2026 to begin clinical development of this TV-enabled anti-amyloid program for Alzheimer’s disease.

Corporate Updates

As previously announced in connection with the approval of AVLAYAH, the FDA granted Denali Therapeutics a Rare Pediatric Disease Priority Review Voucher (PRV). This voucher may be used to obtain priority review for a future marketing application and can be transferred to another sponsor.

On March 27, 2026, Denali received $200 million in gross proceeds in connection with the closing of the transactions under a synthetic royalty funding agreement signed in December 2025 with Royalty Pharma Investments 2023 ICAV.

On April 3, 2026, Denali announced it received notification from Takeda of its decision to terminate the collaboration agreement between the two companies to co-develop and co-commercialize DNL593. Takeda’s decision was driven by strategic considerations and was not related to efficacy or safety data. Denali continues to advance DNL593 in the ongoing Phase 1/2 study in patients with FTD-GRN and expects results by the end of 2026 as described above.

Participation in Upcoming Investor Conferences

Bank of America Healthcare Conference 2026, May 12-14 (Las Vegas)Jefferies Global Healthcare Conference, June 2-4 (New York City)Goldman Sachs 47th Annual Global Healthcare Conference, June 8-10 (Miami)BTIG Virtual Biotechnology Conference, July 28-29 First Quarter 2026 Financial Results

Net loss was $128.4 million for the quarter ended March 31, 2026, compared to net loss of $133.0 million for the quarter ended March 31, 2025.

Total research and development expenses were $103.8 million for the quarter ended March 31, 2026, compared to $116.2 million for the quarter ended March 31, 2025. The decrease of approximately $12.4 million was primarily attributable to the timing of manufacturing of AVLAYAH commercial supply in the first quarter of 2025, as well as lower external expenses related to small molecule programs.

General and administrative expenses were $33.5 million for the quarter ended March 31, 2026, compared to $29.4 million for the quarter ended March 31, 2025. The increase of $4.1 million was primarily driven by higher personnel-related costs due to increased headcount in the first quarter of 2026, reflecting headcount additions made throughout 2025 to support post-launch activities for AVLAYAH.

Cash, cash equivalents and marketable securities were approximately $1.05 billion as of March 31, 2026.

About the Denali TransportVehicle™ Platform

The blood-brain barrier (BBB) is essential in maintaining the brain’s microenvironment and protecting it from harmful substances and pathogens circulating in the bloodstream. Historically, the BBB has posed significant challenges to drug development for central nervous system diseases by preventing most drugs from reaching the brain in therapeutically relevant concentrations. Denali’s TransportVehicle™ (TV) platform is a proprietary technology designed to effectively deliver large therapeutic molecules such as antibodies, enzymes and oligonucleotides throughout the whole body, including the brain, by crossing the BBB after intravenous administration. The TV platform is based on engineered Fc domains that bind to specific natural transport receptors, such as transferrin receptor and CD98 heavy chain amino acid transporter, which are expressed at the BBB and deliver the TV and its therapeutic cargo to the brain through receptor-mediated transcytosis. In animal models, antibodies and enzymes engineered with the TV platform demonstrate more than 10- to 30-fold greater brain exposure than similar antibodies and enzymes without this technology. Oligonucleotides engineered with the TV platform demonstrate more than a 1,000-fold greater brain exposure in primates than systemically delivered oligonucleotides without this technology. Improved exposure and broad distribution in the brain may increase therapeutic efficacy by enabling widespread achievement of therapeutically relevant concentrations of product candidates. The TV platform has been clinically validated, with AVLAYAH™ (tividenofusp alfa-eknm) as the first FDA-approved medicine leveraging transferrin receptor to cross the BBB.

About Denali Therapeutics

Denali Therapeutics Inc. is a biotechnology company pioneering a new class of biotherapeutics designed to cross the blood-brain barrier (BBB) using its proprietary TransportVehicle™ platform. With the first FDA-approved biologic specifically designed to cross the BBB, a clinically validated delivery platform, and a growing portfolio of therapeutic candidates across all stages of development, Denali is advancing toward its goal of delivering effective medicines to transform life for people with neurodegenerative diseases, lysosomal storage disorders and other serious diseases. For more information, please visit www.denalitherapeutics.com.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements expressed or implied in this press release include, but are not limited to, statements regarding expectations for Denali’s TransportVehicle™ (TV) platform, including the Enzyme TransportVehicle™ (ETV) franchise, and its therapeutic and commercial potential; plans, timelines, and expectations relating to the commercial launch of AVLAYAH™ (tividenofusp alfa-eknm) and related activities; expectations related to the ongoing Phase 2/3 COMPASS study of tividenofusp alfa, including the timing and availability of data and its ability to generate confirmatory evidence and support global regulatory submissions; plans, timelines and expectations related to DNL126, including the ongoing Phase 1/2 study, the planned Phase 3 confirmatory study, the planned BLA submission, and the likelihood and timing of accelerated approval; plans, timelines and expectations related to DNL593, including the ongoing Phase 1/2 study, the timing and availability of data, and Denali’s ability to independently advance the program; plans, timelines and expectations related to DNL628, including the ongoing Phase 1b study and the timing and availability of data; plans, timelines and expectations related to DNL952 and the planned Phase 1 study; plans, timelines and expectations related to DNL151, including the ongoing Phase 2a BEACON study, and the timing and availability of data from the Phase 2b LUMA study; plans, timelines and expectations related to DNL921, including the expected timing of a regulatory filing and initiation of clinical development; plans, timelines, and expectations for IND-enabling stage programs; plans and expectations regarding Denali's Rare Pediatric Disease Priority Review Voucher; expectations regarding the Royalty Pharma funding agreement, including royalty payment obligations and milestones; plans regarding participation in upcoming investor conferences; and statements by Denali's Chief Executive Officer. Actual results may differ materially from those expressed or implied by these forward-looking statements due to a variety of risks and uncertainties. These include, but are not limited to, uncertainties related to the FDA’s policies and accelerated approval program; risks arising from adverse economic conditions and their impact on Denali’s business and operations; the possibility of events or changes that could lead to the termination of Denali’s collaboration agreements; challenges associated with Denali’s transition to a commercial company; the ability of Denali and its collaborators to complete the development and, if approved, the commercialization of product candidates; difficulties in patient enrollment for ongoing and future clinical trials; whether the current ongoing trials have been powered sufficiently to demonstrate approvability to regulatory agencies; reliance on third-party manufacturers and suppliers for clinical trial materials; dependence on the successful development of Denali’s blood-brain barrier platform technology and related programs; potential delays or failures in meeting expected clinical trial timelines; discrepancies between preclinical, early-stage or preliminary clinical results and outcomes from later-stage trials; the risk that interim or topline clinical results may not be predictive of final study results or longer‑term outcomes; the occurrence of significant adverse events or other undesirable side effects; the uncertainty surrounding regulatory approvals required for commercialization in the U.S., Europe or other international jurisdictions; Denali’s ability to advance a pipeline of product candidates or develop commercially successful products; developments relating to Denali's competitors and competing product candidates; Denali’s ability to obtain, maintain or protect intellectual property rights related to its product candidates; the implementation and success of Denali’s strategic plans for its business, product candidates and blood-brain barrier platform technology; Denali's ability to obtain additional capital to finance its operations, as needed; Denali's ability to accurately forecast future financial results in the current environment; and other risks and uncertainties, including those described in Denali's most recent Annual Report on Form 10-K filed with the Securities and Exchange Commission (SEC) on February 26, 2026, and Denali’s future reports to be filed with the SEC. Except for AVLAYAH, Denali's product candidates are investigational, and their safety and efficacy profiles have not yet been established. Denali does not undertake any obligation to update or revise any forward-looking statements, to conform these statements to actual results or to make changes in Denali’s expectations, except as required by law.

  Denali Therapeutics Inc.
Condensed Consolidated Statements of Operations
(Unaudited)
(In thousands, except share and per share amounts)   Three Months Ended March 31,  2026   2025 Operating expenses:   Research and development$103,846  $116,227 General and administration 33,511   29,353 Total operating expenses 137,357   145,580 Loss from operations (137,357)  (145,580)Interest and other income, net 8,910   12,610 Net loss$(128,447) $(132,970)Net loss per share, basic and diluted$(0.69) $(0.78)Weighted average number of shares outstanding, basic and diluted 186,636,978   171,222,030          Denali Therapeutics Inc.
Condensed Consolidated Balance Sheets
(Unaudited)
(In thousands)     March 31,
2026 December 31,
2025Assets   Current assets:   Cash and cash equivalents$387,626 $205,326Short-term marketable securities 600,058  662,553Prepaid expenses and other current assets 35,068  32,779Total current assets 1,022,752  900,658Long-term marketable securities 63,785  98,322Property and equipment, net 51,728  52,402Finance lease right-of-use asset 47,616  48,531Operating lease right-of-use asset 17,922  19,002Intangible asset, net 36,000  —Other non-current assets 26,220  25,939Total assets$1,266,023 $1,144,854Liabilities and stockholders' equity   Current liabilities:   Accounts payable$40,380 $505Accrued expenses and other current liabilities 69,776  76,745Total current liabilities 110,156  98,351Operating lease liability, less current portion 24,680  27,210Finance lease liability, less current portion 5,508  5,532Liability related to the revenue participation right agreement 199,581  —Total liabilities 339,925  131,093Total stockholders' equity 926,098  1,013,761Total liabilities and stockholders’ equity$1,266,023 $1,144,854             Investor Contact:
Laura Hansen, Ph.D.
[email protected]

Media Contact:
Erin Patton
[email protected]

Denali Therapeutics Inc. (DNLI) Presents at Bank of America Global Healthcare Conference 2026 Transcript

On May 15, 2026, ADAR1 Capital Management disclosed in an SEC filing that it bought 1,819,339 Denali Therapeutics shares, an estimated $36.20 million trade based on quarterly average pricing.

What happenedAccording to a Securities and Exchange Commission (SEC) filing dated May 15, 2026, ADAR1 Capital Management, increased its position in Denali Therapeutics (DNLI +4.78%) by 1,819,339 shares during the first quarter of 2026. The estimated transaction value was $36.20 million, based on the average unadjusted closing price for the quarter. The quarter-end valuation for the position rose by $35.07 million, a figure that includes both additional shares and market price changes.

What else to knowThis buy brings the Denali Therapeutics stake to 2.12% of ADAR1’s reported equity assets after the first quarter.Top holdings after the filing:NASDAQ: ABVX: $155.22 million (9.4% of AUM)NASDAQ: PTGX: $104.78 million (6.4% of AUM)NASDAQ: ROIV: $91.02 million (5.5% of AUM)NASDAQ: IMVT: $66.55 million (4.0% of AUM)NYSEMKT: SPY: $49.39 million (3.0% of AUM)As of May 17, 2026, Denali Therapeutics shares were priced at $18.62, up 31.5% over the past year, outperforming the S&P 500 by 6.29 percentage points.Company OverviewMetricValueMarket Capitalization$2.96 billionEmployees443Net Income (TTM)$-508.02 millionPrice (as of market close 2026-05-15)$18.62Company SnapshotDevelops therapeutic candidates for neurodegenerative diseases, including Parkinson's disease, Hunter syndrome, ALS, multiple sclerosis, Alzheimer's disease, and lupus, with several candidates in Phase I and II clinical trials.Operates a biotechnology business model focused on drug discovery and development, generating revenue primarily through research collaborations and licensing agreements with major pharmaceutical partners.Targets healthcare providers, pharmaceutical companies, and patients affected by neurodegenerative and rare diseases in the United States and globally.Denali Therapeutics is a clinical-stage biopharmaceutical company specializing in the development of innovative therapies for neurodegenerative diseases. The company's strategy emphasizes advancing a diversified pipeline through strategic collaborations with leading pharmaceutical firms.

Today's Change

(

4.78

%) $

1.00

Current Price

$

22.02

What this transaction means for investorsInvesting in a biotech that just got its first drug approved is betting the science behind that success can be repeated across multiple diseases. Hedge fund ADAR1 Capital Management made that bet with a $36 million Denali Therapeutics position in Q1.

Denali recently achieved a major milestone with FDA approval for its first commercial drug, treating a rare brain disease. What makes this significant is the technology behind it. The company developed a platform that solves a longstanding medical problem: getting drugs into the brain. Most therapies can't cross the protective barrier around the brain, limiting treatment options for neurological diseases.

The company has substantial cash reserves and is developing treatments for Alzheimer's, Parkinson's, and other brain conditions using the same underlying technology.

For average investors, this is high-risk, high-reward investing. If the platform proves it can deliver multiple successful drugs, the upside is enormous. If future candidates fail or the technology doesn't work as broadly as hoped, the stock could struggle despite the initial success.

Sara Appino has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Denali Therapeutics. The Motley Fool recommends Protagonist Therapeutics and Roivant Sciences. The Motley Fool has a disclosure policy.

Denali Therapeutics (DNLI) maintains a "Strong Buy" rating following FDA Accelerated Approval of AVLAYAH for Hunter Syndrome and robust pipeline momentum. Company's DNL593 for FTD-GRN is differentiated by restoring both extracellular and lysosomal PGRN; phase 1/2 data readout expected by end of 2026. AVLAYAH's full approval depends on confirmatory COMPASS study results; commercial performance remains unproven post-April 2026 launch.

Taking full advantage of the stock market and investing with confidence are common goals for new and old investors, and Zacks Premium offers many different ways to do both.

The research service features daily updates of the Zacks Rank and Zacks Industry Rank, full access to the Zacks #1 Rank List, Equity Research reports, and Premium stock screens, all of which will help you become a smarter, more confident investor.

Zacks Premium includes access to the Zacks Style Scores as well.

What are the Zacks Style Scores? The Zacks Style Scores is a unique set of guidelines that rates stocks based on three popular investing types, and were developed as complementary indicators for the Zacks Rank. This combination helps investors choose securities with the highest chances of beating the market over the next 30 days.

Each stock is assigned a rating of A, B, C, D, or F based on their value, growth, and momentum characteristics. Just like in school, an A is better than a B, a B is better than a C, and so on -- that means the better the score, the better chance the stock will outperform.

The Style Scores are broken down into four categories:

Value ScoreValue investors love finding good stocks at good prices, especially before the broader market catches on to a stock's true value. Utilizing ratios like P/E, PEG, Price/Sales, Price/Cash Flow, and many other multiples, the Value Style Score identifies the most attractive and most discounted stocks.

Growth ScoreGrowth investors are more concerned with a stock's future prospects, and the overall financial health and strength of a company. Thus, the Growth Style Score analyzes characteristics like projected and historic earnings, sales, and cash flow to find stocks that will see sustainable growth over time.

Momentum ScoreMomentum trading is all about taking advantage of upward or downward trends in a stock's price or earnings outlook, and these investors live by the saying "the trend is your friend." The Momentum Style Score can pinpoint good times to build a position in a stock, using factors like one-week price change and the monthly percentage change in earnings estimates.

VGM ScoreIf you like to use all three kinds of investing, then the VGM Score is for you. It's a combination of all Style Scores, and is an important indicator to use with the Zacks Rank. The VGM Score rates each stock on their shared weighted styles, narrowing down the companies with the most attractive value, best growth forecast, and most promising momentum.

How Style Scores Work with the Zacks Rank A proprietary stock-rating model, the Zacks Rank utilizes the power of earnings estimate revisions, or changes to a company's earnings outlook, to help investors create a successful portfolio.

Investors can count on the Zacks Rank's success, with #1 (Strong Buy) stocks producing an unmatched +23.7% average annual return since 1988, more than double the S&P 500's performance. But the model rates a large number of stocks, and there are over 200 companies with a Strong Buy rank, plus another 600 with a #2 (Buy) rank, on any given day.

This totals more than 800 top-rated stocks, and it can be overwhelming to try and pick the best stocks for you and your portfolio.

That's where the Style Scores come in.

To maximize your returns, you want to buy stocks with the highest probability of success. This means picking stocks with a Zacks Rank #1 or #2 that also have Style Scores of A or B. If you find yourself looking at stocks with a #3 (Hold) rank, make sure they have Scores of A or B as well to ensure as much upside potential as possible.

The direction of a stock's earnings estimate revisions should always be a key factor when choosing which stocks to buy, since the Scores were created to work together with the Zacks Rank.

A stock with a #4 (Sell) or #5 (Strong Sell) rating, for instance, even one with Scores of A and B, will still have a declining earnings forecast, and a greater chance its share price will fall too.

Thus, the more stocks you own with a #1 or #2 Rank and Scores of A or B, the better.

Stock to Watch: Teradata (TDC - Free Report) Teradata offers an open and connected hybrid cloud analytics and data platform for AI. The hybrid cloud platform, named Teradata Vantage, help enterprises solve business problems with Teradata’s capabilities to provide harmonized data, trusted AI, and faster innovation, at scale.

TDC is a #2 (Buy) on the Zacks Rank, with a VGM Score of A.

Additionally, the company could be a top pick for growth investors. TDC has a Growth Style Score of B, forecasting year-over-year earnings growth of 1.9% for the current fiscal year.

For fiscal 2026, one analyst revised their earnings estimate upwards in the last 60 days, and the Zacks Consensus Estimate has increased $0.02 to $2.63 per share. TDC boasts an average earnings surprise of +24.8%.

With a solid Zacks Rank and top-tier Growth and VGM Style Scores, TDC should be on investors' short list.

Company earns top ranking in Analytic Data Platforms, demonstrating leadership across the full spectrum of AI and data innovation

, /PRNewswire/ -- Teradata (NYSE: TDC) today announced it has been recognized as Exemplary — the highest designation — across seven evaluated categories in the 2026 ISG Buyers Guides™ for AI and Data Platforms, a comprehensive independent research study led by ISG analysts Dave Menninger and Matt Aslett. Teradata earned its strongest ranking in the Analytic Data Platforms Buyers Guide, underscoring the company's continued leadership in delivering enterprise-grade analytics at scale.

What This Recognition Means
Being classified as Exemplary — the top tier — across all seven evaluated categories reflects Teradata's depth of capability and consistent execution across the AI and data platform landscape. The recognition highlights the company's ability to meet evolving enterprise requirements spanning performance, governance, scalability, and real-world AI deployment.

How ISG Evaluates AI and Data Platform Vendors
The ISG Buyers Guides™ evaluate technology providers on their ability to satisfy current and future requirements across three core dimensions: product capabilities, customer experience, and market impact. The research is designed to help organizations make informed technology decisions based on independent, analyst-led evaluation.

Where Teradata Ranked as 'Exemplary'
Teradata received the Exemplary designation in the following ISG Buyers Guides™:

Analytic Data Platforms AI and Data Platforms Sovereign AI and Data AI Agents Agentic and Generative AI AI Platforms AI Governance and Operations Analyst Commentary
"Teradata has demonstrated broad strength across the AI and data platform landscape. Their top-ranking performance in Analytic Data Platforms, combined with Exemplary-level recognition across six additional categories, reflects a mature, enterprise-ready approach to helping organizations harness the full value of their data."

— Dave Menninger, Executive Director and Distinguished Analyst, ISG Research

Executive Commentary
"What we're hearing consistently from customers and partners is that organizations need and recognize Teradata's mature, enterprise-ready approach to AI and data — and this recognition from ISG reflects that. Being named Exemplary across seven categories, with our strongest performance in Analytic Data Platforms, is a testament to the hard work of our teams and the trust our customers place in us. As enterprises accelerate their AI and data strategies, as an ISG Exemplary designee, we believe Teradata is uniquely positioned to help them scale secure, governed AI and advanced analytics across hybrid, cloud, and on-premises environments."

— Richard Petley, Chief Revenue Officer, Teradata

Why This Matters for Enterprise AI and Data Strategies
Teradata's recognition spans the full breadth of modern AI and data priorities — from foundational analytic platforms and cloud-scale AI infrastructure to agentic AI, governance, and sovereign data requirements — reflecting the company's commitment to meeting enterprises wherever they are in their data journey.

About Teradata
Teradata empowers enterprises to turn intelligence into autonomous action, grounding AI agents in deep business context and trusted data. As AI agents multiply, Teradata is the context foundation, governance layer, and performance backbone that companies need now. The Teradata Autonomous Knowledge platform puts AI into production across cloud, on-premises, and hybrid environments.

The Teradata logo is a trademark, and Teradata is a registered trademark of Teradata Corporation and/or its affiliates in the U.S. and worldwide.

MEDIA CONTACT
January Machold
[email protected]

SOURCE Teradata Corporation

On May 13, 2026, Teradata Corp (TDC) shares rose 3.0% to $32.70. This increase is notable within the broader context of the stock's price performance, as it has

The on-premises deployment of the Teradata Autonomous Knowledge Platform — private AI and enterprise-grade performance across hybrid environments

, /PRNewswire/ -- Hybrid is the operating reality for many enterprises running AI at scale. The trade-offs that come with it are not.

Teradata (NYSE: TDC) today announced the Teradata Factory, extending the Teradata Autonomous Knowledge Platform with a fully integrated on-premises foundation for enterprises running AI and analytics in hybrid environments. Built on Dell Technologies enterprise compute and storage, it unifies the complete Teradata software stack — including AI Studio — within a single management plane, supporting EDW, Lakehouse, and advanced AI workloads with enterprise-grade performance, private AI, and hybrid/multi-cloud flexibility built in.

What is Autonomous Knowledge?
Autonomous Knowledge is the ability of an enterprise software platform to turn structured and unstructured data, operating models and experience into trusted, governed understanding, decisions and actions. Grounded in industry-specific data, semantics, and lineage, it provides the business context for agentic AI to sense, decide, and act reliably and repeatedly across systems and tools — with minimal human intervention — while learning and improving over time.

Teradata Autonomous Knowledge Platform: On-Premises Deployment Highlights
The Factory runs EDW, Lakehouse, and advanced AI workloads on a single, integrated system. It includes the complete Teradata software suite introduced with the Teradata Autonomous Knowledge Platform — including AI Studio — ensuring consistent capabilities, governance, and management across cloud and on-premises deployments. Key elements include:

On-premises foundation for an AI-native, agentic enterprise Integrated and ready to run with CPUs and GPUs Modular scale with predictable economics Workload management between mission-critical and experimental Open and hybrid by default with OTF support Dell Technologies is a strategic collaborator for this on-premises deployment. Teradata integrates with the Dell AI Factory and Dell AI Data Platform — enabling the underlying data management foundation to ensure enterprise data is AI-ready: curated, governed, and accessible at the speed AI demands.

Teradata delivers the fully integrated software stack, management plane, and customer experience as a complete Teradata product — the on-premises element that complements cloud deployments and extends Teradata's trusted analytics footprint into the AI era.

Why It Matters
As AI and agentic workloads move into production, the infrastructure calculus is changing — GPU consumption, continuous inference, and data-intensive analytics are exposing the limits of public cloud economics in ways that traditional workloads never did. For regulated industries and the public sector, the pressure is even greater — hybrid and private AI are becoming requirements as organizations balance local control and data residency with multi-cloud flexibility. And as agentic AI moves from pilot to production, the real challenge is operationalizing it within the constraints that matter — governance, reliability, and cost control.

Why Teradata
Most on-premises AI infrastructure approaches shift cost and complexity rather than eliminate it — requiring enterprises to assemble, integrate, and maintain separate components across compute, storage, GPUs, database engines, AI tooling, and orchestration, each with its own pricing model and integration risk. The on-premises deployment of the Teradata Autonomous Knowledge Platform takes a different approach: one pre-engineered system, one management plane, and a fully integrated software and hardware stack delivered as a Teradata product — with the open architecture, performance, and cost control that AI at scale demands.

Executive Quotes
"The data platform and the AI platform are converging — yet most enterprises are still running AI far from their most critical data. The Teradata Factory brings EDW reliability, Lakehouse flexibility, and AI horsepower together in a single on-premises system — so enterprises get the full performance of the Teradata Autonomous Knowledge Platform wherever their data, regulations, and agents require."

— Sumeet Arora, Chief Product Officer, Teradata

"Data sovereignty is evolving beyond just a compliance requirement. It is becoming a core architectural decision as AI moves from pilot to production. Enterprises are realizing that where AI runs can be as important as how it runs. This on-premises deployment of the Teradata Autonomous Knowledge Platform can give enterprises a more direct path to run private AI on-premises, keeping it close to the data and under their governance, while maintaining the control, consistency, and performance needed at scale."

— Robert B. Kramer, Managing Partner, KramerERP

Platform Capabilities: On-Premises

On-premises foundation for an AI-native, agentic enterprise: This deployment is designed to deliver on-premises AI without compromise — the private AI controls, governance, and hybrid deployment model that make agents possible in regulated, mission-critical environments. Central to that is AI Studio, pre-integrated and ready to run on day one — bringing the full AI lifecycle on-premises, from data to models to agents to applications, with no data movement required. AI that runs where the data lives delivers fundamentally different performance, governance, and context than AI operating at a distance from it. As part of the Teradata Autonomous Knowledge Platform, this deployment provides a clear modernization path to an AI-native infrastructure foundation — ensuring enterprises have consistent governance, connected data, and agentic UX across cloud and on-premises environments as they scale.

Integrated and Ready to Run with GPUs: The on-premises deployment of the Teradata Autonomous Knowledge Platform delivers Dell enterprise compute and storage, AI Studio, and the complete Teradata software suite as a single pre-engineered system — running GenAI, LLMs, ML/DL, and classic analytics side-by-side, on-premises, ready from day one across EDW, Lakehouse, and advanced AI workloads. Customers don't source, integrate, or validate these components independently, reducing setup time and eliminating dependency sprawl while delivering a high-performing foundation for analytics and AI operations.

Modular Scale with Predictable Economics: A new management cluster and converged Ethernet fabric unify compute, storage, GPU, and networking under a single management plane, supporting modular expansion from pilot to production on the enterprise's timeline. Fixed infrastructure economics eliminate per-query, per-GPU, and data movement fees — designed specifically for analytics and AI at scale.

Autonomous Platform Management with Tera Agents: The Teradata Autonomous Knowledge Platform includes Tera — a set of pre-built platform agents that perform infrastructure and operational tasks autonomously, continuously and without manual intervention. Tera agents monitor and manage compute resources, optimize query execution, process telemetry, and control cloud and on-premises spend, reducing IT operational burden while keeping performance and cost on target.

Workload Management Between Mission-Critical and Experimental: Active System Management automatically maintains performance and SLAs for vital analytics while AI teams run exploratory or resource-intensive tasks — no resource contention, no trade-offs. The result is the control and compliance of private AI with enterprise-grade performance — keeping revenue-critical operations protected and compliant.

Open and Hybrid by Default: Support for Apache Iceberg, Delta Lake, and S3-compatible object storage reduces lock-in, protects existing investments, and links to the Connected Data Foundation and the Teradata Cloud — ensuring data is stored once and accessed consistently across cloud and on-premises environments.

Availability
The Teradata Factory is expected to be available in Q3 2026.

About Teradata
Teradata empowers enterprises to turn intelligence into autonomous action, grounding AI agents in deep business context and trusted data. As AI agents multiply, Teradata is the context foundation, governance layer, and performance backbone that companies need now. The Teradata Autonomous Knowledge Platform puts AI into production across cloud, on-premises, and hybrid environments.

The Teradata logo is a trademark, and Teradata is a registered trademark of Teradata Corporation and/or its affiliates in the U.S. and worldwide.

MEDIA CONTACT
Jennifer Donahue
[email protected]

SOURCE Teradata

Teradata (TDC - Free Report) appears an attractive pick, as it has been recently upgraded to a Zacks Rank #2 (Buy). An upward trend in earnings estimates -- one of the most powerful forces impacting stock prices -- has triggered this rating change.

A company's changing earnings picture is at the core of the Zacks rating. The system tracks the Zacks Consensus Estimate -- the consensus measure of EPS estimates from the sell-side analysts covering the stock -- for the current and following years.

The power of a changing earnings picture in determining near-term stock price movements makes the Zacks rating system highly useful for individual investors, since it can be difficult to make decisions based on rating upgrades by Wall Street analysts. These are mostly driven by subjective factors that are hard to see and measure in real time.

As such, the Zacks rating upgrade for Teradata is essentially a positive comment on its earnings outlook that could have a favorable impact on its stock price.

Most Powerful Force Impacting Stock PricesThe change in a company's future earnings potential, as reflected in earnings estimate revisions, and the near-term price movement of its stock are proven to be strongly correlated. The influence of institutional investors has a partial contribution to this relationship, as these big professionals use earnings and earnings estimates to calculate the fair value of a company's shares. An increase or decrease in earnings estimates in their valuation models simply results in higher or lower fair value for a stock, and institutional investors typically buy or sell it. Their transaction of large amounts of shares then leads to price movement for the stock.

For Teradata, rising earnings estimates and the consequent rating upgrade fundamentally mean an improvement in the company's underlying business. And investors' appreciation of this improving business trend should push the stock higher.

Harnessing the Power of Earnings Estimate RevisionsAs empirical research shows a strong correlation between trends in earnings estimate revisions and near-term stock movements, tracking such revisions for making an investment decision could be truly rewarding. Here is where the tried-and-tested Zacks Rank stock-rating system plays an important role, as it effectively harnesses the power of earnings estimate revisions.

The Zacks Rank stock-rating system, which uses four factors related to earnings estimates to classify stocks into five groups, ranging from Zacks Rank #1 (Strong Buy) to Zacks Rank #5 (Strong Sell), has an impressive externally-audited track record, with Zacks Rank #1 stocks generating an average annual return of +25% since 1988. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here >>>> .

Earnings Estimate Revisions for TeradataThis data management company is expected to earn $2.65 per share for the fiscal year ending December 2026, which represents no year-over-year change.

Analysts have been steadily raising their estimates for Teradata. Over the past three months, the Zacks Consensus Estimate for the company has increased 0.5%.

Bottom LineUnlike the overly optimistic Wall Street analysts whose rating systems tend to be weighted toward favorable recommendations, the Zacks rating system maintains an equal proportion of "buy" and "sell" ratings for its entire universe of more than 4,000 stocks at any point in time. Irrespective of market conditions, only the top 5% of the Zacks-covered stocks get a "Strong Buy" rating and the next 15% get a "Buy" rating. So, the placement of a stock in the top 20% of the Zacks-covered stocks indicates its superior earnings estimate revision feature, making it a solid candidate for producing market-beating returns in the near term.

You can learn more about the Zacks Rank here >>>

The upgrade of Teradata to a Zacks Rank #2 positions it in the top 20% of the Zacks-covered stocks in terms of estimate revisions, implying that the stock might move higher in the near term.

For new and old investors, taking full advantage of the stock market and investing with confidence are common goals. Zacks Premium provides lots of different ways to do both.

The popular research service can help you become a smarter, more self-assured investor, giving you access to daily updates of the Zacks Rank and Zacks Industry Rank, the Zacks #1 Rank List, Equity Research reports, and Premium stock screens.

Zacks Premium includes access to the Zacks Style Scores as well.

What are the Zacks Style Scores? Developed alongside the Zacks Rank, the Zacks Style Scores are a group of complementary indicators that help investors pick stocks with the best chances of beating the market over the next 30 days.

Based on their value, growth, and momentum characteristics, each stock is assigned a rating of A, B, C, D, or F. The better the score, the better chance the stock will outperform; an A is better than a B, a B is better than a C, and so on.

The Style Scores are broken down into four categories:

Value ScoreValue investors love finding good stocks at good prices, especially before the broader market catches on to a stock's true value. Utilizing ratios like P/E, PEG, Price/Sales, Price/Cash Flow, and many other multiples, the Value Style Score identifies the most attractive and most discounted stocks.

Growth ScoreGrowth investors, on the other hand, are more concerned with a company's financial strength and health, and its future outlook. The Growth Style Score examines things like projected and historic earnings, sales, and cash flow to find stocks that will experience sustainable growth over time.

Momentum ScoreMomentum traders and investors live by the saying "the trend is your friend." This investing style is all about taking advantage of upward or downward trends in a stock's price or earnings outlook. Employing factors like one-week price change and the monthly percentage change in earnings estimates, the Momentum Style Score can indicate favorable times to build a position in high-momentum stocks.

VGM ScoreIf you want a combination of all three Style Scores, then the VGM Score will be your friend. It rates each stock on their combined weighted styles, helping you find the companies with the most attractive value, best growth forecast, and most promising momentum. It's also one of the best indicators to use with the Zacks Rank.

How Style Scores Work with the Zacks Rank A proprietary stock-rating model, the Zacks Rank utilizes the power of earnings estimate revisions, or changes to a company's earnings outlook, to help investors create a successful portfolio.

#1 (Strong Buy) stocks have produced an unmatched +23.7% average annual return since 1988, which is more than double the S&P 500's performance over the same time frame. However, the Zacks Rank examines a ton of stocks, and there can be more than 200 companies with a Strong Buy rank, and another 600 with a #2 (Buy) rank, on any given day.

With more than 800 top-rated stocks to choose from, it can certainly feel overwhelming to pick the ones that are right for you and your investing journey.

That's where the Style Scores come in.

To maximize your returns, you want to buy stocks with the highest probability of success. This means picking stocks with a Zacks Rank #1 or #2 that also have Style Scores of A or B. If you find yourself looking at stocks with a #3 (Hold) rank, make sure they have Scores of A or B as well to ensure as much upside potential as possible.

Since the Scores were created to work together with the Zacks Rank, the direction of a stock's earnings estimate revisions should be a key factor when choosing which stocks to buy.

Here's an example: a stock with a #4 (Sell) or #5 (Strong Sell) rating, even one with Style Scores of A and B, still has a downward-trending earnings outlook, and a bigger chance its share price will decrease too.

Thus, the more stocks you own with a #1 or #2 Rank and Scores of A or B, the better.

Stock to Watch: Teradata (TDC - Free Report) Teradata offers an open and connected hybrid cloud analytics and data platform for AI. The hybrid cloud platform, named Teradata Vantage, help enterprises solve business problems with Teradata’s capabilities to provide harmonized data, trusted AI, and faster innovation, at scale.

TDC is a #2 (Buy) on the Zacks Rank, with a VGM Score of A.

Momentum investors should take note of this Computer and Technology stock. TDC has a Momentum Style Score of B, and shares are up 22.7% over the past four weeks.

Two analysts revised their earnings estimate upwards in the last 60 days for fiscal 2026. The Zacks Consensus Estimate has increased $0.04 to $2.65 per share. TDC boasts an average earnings surprise of +24.8%.

With a solid Zacks Rank and top-tier Momentum and VGM Style Scores, TDC should be on investors' short list.

For new and old investors, taking full advantage of the stock market and investing with confidence are common goals. Zacks Premium provides lots of different ways to do both.

The popular research service can help you become a smarter, more self-assured investor, giving you access to daily updates of the Zacks Rank and Zacks Industry Rank, the Zacks #1 Rank List, Equity Research reports, and Premium stock screens.

Zacks Premium includes access to the Zacks Style Scores as well.

What are the Zacks Style Scores? The Zacks Style Scores is a unique set of guidelines that rates stocks based on three popular investing types, and were developed as complementary indicators for the Zacks Rank. This combination helps investors choose securities with the highest chances of beating the market over the next 30 days.

Each stock is given an alphabetic rating of A, B, C, D or F based on their value, growth, and momentum qualities. With this system, an A is better than a B, a B is better than a C, and so on, meaning the better the score, the better chance the stock will outperform.

The Style Scores are broken down into four categories:

Value ScoreFor value investors, it's all about finding good stocks at good prices, and discovering which companies are trading under their true value before the broader market catches on. The Value Style Score utilizes ratios like P/E, PEG, Price/Sales, Price/Cash Flow, and a host of other multiples to help pick out the most attractive and discounted stocks.

Growth ScoreWhile good value is important, growth investors are more focused on a company's financial strength and health, and its future outlook. The Growth Style Score takes projected and historic earnings, sales, and cash flow into account to uncover stocks that will see long-term, sustainable growth.

Momentum ScoreMomentum trading is all about taking advantage of upward or downward trends in a stock's price or earnings outlook, and these investors live by the saying "the trend is your friend." The Momentum Style Score can pinpoint good times to build a position in a stock, using factors like one-week price change and the monthly percentage change in earnings estimates.

VGM ScoreIf you like to use all three kinds of investing, then the VGM Score is for you. It's a combination of all Style Scores, and is an important indicator to use with the Zacks Rank. The VGM Score rates each stock on their shared weighted styles, narrowing down the companies with the most attractive value, best growth forecast, and most promising momentum.

How Style Scores Work with the Zacks Rank The Zacks Rank is a proprietary stock-rating model that harnesses the power of earnings estimate revisions, or changes to a company's earnings expectations, to help investors build a successful portfolio.

It's highly successful, with #1 (Strong Buy) stocks producing an unmatched +23.7% average annual return since 1988. That's more than double the S&P 500. But because of the large number of stocks we rate, there are over 200 companies with a Strong Buy rank, plus another 600 with a #2 (Buy) rank, on any given day.

With more than 800 top-rated stocks to choose from, it can certainly feel overwhelming to pick the ones that are right for you and your investing journey.

That's where the Style Scores come in.

To maximize your returns, you want to buy stocks with the highest probability of success. This means picking stocks with a Zacks Rank #1 or #2 that also have Style Scores of A or B. If you find yourself looking at stocks with a #3 (Hold) rank, make sure they have Scores of A or B as well to ensure as much upside potential as possible.

The direction of a stock's earnings estimate revisions should always be a key factor when choosing which stocks to buy, since the Scores were created to work together with the Zacks Rank.

For instance, a stock with a #4 (Sell) or #5 (Strong Sell) rating, even one that boasts Scores of A and B, still has a downward-trending earnings forecast, and a much greater likelihood its share price will decline as well.

Thus, the more stocks you own with a #1 or #2 Rank and Scores of A or B, the better.

Stock to Watch: Teradata (TDC - Free Report) Teradata offers an open and connected hybrid cloud analytics and data platform for AI. The hybrid cloud platform, named Teradata Vantage, help enterprises solve business problems with Teradata’s capabilities to provide harmonized data, trusted AI, and faster innovation, at scale.

TDC is a #2 (Buy) on the Zacks Rank, with a VGM Score of A.

Additionally, the company could be a top pick for growth investors. TDC has a Growth Style Score of A, forecasting year-over-year earnings growth of 2.7% for the current fiscal year.

Two analysts revised their earnings estimate upwards in the last 60 days for fiscal 2026. The Zacks Consensus Estimate has increased $0.04 to $2.65 per share. TDC boasts an average earnings surprise of +24.8%.

With a solid Zacks Rank and top-tier Growth and VGM Style Scores, TDC should be on investors' short list.

Investors with an interest in Computer- Storage Devices stocks have likely encountered both Teradata (TDC - Free Report) and NetApp (NTAP - Free Report) . But which of these two companies is the best option for those looking for undervalued stocks? Let's take a closer look.

We have found that the best way to discover great value opportunities is to pair a strong Zacks Rank with a great grade in the Value category of our Style Scores system. The proven Zacks Rank emphasizes companies with positive estimate revision trends, and our Style Scores highlight stocks with specific traits.

Right now, Teradata is sporting a Zacks Rank of #2 (Buy), while NetApp has a Zacks Rank of #4 (Sell). This means that TDC's earnings estimate revision activity has been more impressive, so investors should feel comfortable with its improving analyst outlook. But this is only part of the picture for value investors.

Value investors also tend to look at a number of traditional, tried-and-true figures to help them find stocks that they believe are undervalued at their current share price levels.

Our Value category grades stocks based on a number of key metrics, including the tried-and-true P/E ratio, the P/S ratio, earnings yield, and cash flow per share, as well as a variety of other fundamentals that value investors frequently use.

TDC currently has a forward P/E ratio of 13.79, while NTAP has a forward P/E of 20.16. We also note that TDC has a PEG ratio of 1.80. This popular figure is similar to the widely-used P/E ratio, but the PEG ratio also considers a company's expected EPS growth rate. NTAP currently has a PEG ratio of 2.64.

Another notable valuation metric for TDC is its P/B ratio of 6.17. The P/B ratio is used to compare a stock's market value with its book value, which is defined as total assets minus total liabilities. For comparison, NTAP has a P/B of 25.65.

These metrics, and several others, help TDC earn a Value grade of B, while NTAP has been given a Value grade of D.

TDC is currently sporting an improving earnings outlook, which makes it stick out in our Zacks Rank model. And, based on the above valuation metrics, we feel that TDC is likely the superior value option right now.

Companies are scrambling to find funds to invest heavily in AI, and some employees' benefits and pay are on the chopping block. EschCollection/Getty Images AI isn't just coming for your job. It's coming for your pay.

As companies look for cash to fund their AI transformations, some are finding it by shrinking employee benefits and compensation packages.

Teradata, a global cloud software company, told its 5,100 employees in January not to expect an annual salary raise this year as it reallocates the budget toward AI investments, according to an internal memo seen by Business Insider and not previously reported.

Teradata's focus for 2026 is to "win in the market with AI," CEO Steve McMillan said in the memo, and to help achieve that, the company will be increasing investment in AI talent and expertise.

"We will fund this AI investment by reallocating the budget from 2026 annual salary adjustments," said McMillan.

Teradata did not comment on the budget decision. A spokesperson told Business Insider that the company is actively investing in AI to innovate its products and services.

Two US-based Teradata employees, both of whom have been at the company for over 10 years, told Business Insider they generally received annual salary increases of 2% to 4%, though they said the increases were not guaranteed each year.

Employees may still receive performance-based bonuses and equity shares as part of their compensation, the memo said. The decision applies to employees in countries where regulators do not require market-aligned salary adjustments.

Teradata is the second company that Business Insider has reported is openly telling staff it is pursuing AI spending over workforce investment.

TTEC, a midsize technology and services firm, recently paused 401(k) matches for its US employees through the end of 2026, saying in internal communications that the benefits retreat would help fund the tools, training, and capabilities necessary for the company's AI future.

The candor with which leaders are naming AI as the reason for cuts marks a new rhetorical shift, said Jennifer Moss, a workplace strategist and the author of "Why Are We Here? Creating a Work Culture Everyone Wants."

"Whether that's more honest or more cynical depends on your read, but it does mark a real shift in what leaders are willing to say in public," Moss said. "And what becomes sayable tends to become more doable."

Financing an AI transformationTTEC and Teradata are technology services companies operating in an industry where failure to adapt to AI is seen as a particularly existential risk. Across industries, businesses are increasing their AI spending. 

A recent CIO survey from RBC Capital polled 117 IT professionals at companies with annual revenues from under $250 million to more than $25 billion. It found that 90% of those surveyed planned to increase AI spending in 2026.

AI spending can range from tens of thousands of dollars for small pilots or basic integrations to millions of dollars for enterprise-scale AI transformations. Those costs are hitting as many companies are already operating with tighter budgets, driven by inflation, tariffs, and supply chain disruptions.

Teradata and TTEC have both faced financial difficulty in recent years, with global revenue declining 5% and 3.2%, respectively, in each company's latest financial year.

While AI costs may be rising, cutting worker compensation is a choice, not an inevitability, Moss told Business Insider.

Transformations can be financed through measures like taking on debt, reallocating nonessential spending, adjusting executive compensation, making acquisitions, phasing investments over time, or accepting lower margins for a defined period, she added.

Alphabet, for example, announced this week that it plans to sell $80 billion in stock to fund its investments in AI infrastructure.

"The reason workforce compensation ends up being the source is that it's the largest controllable expense line at most companies and the one with the least organized resistance," said Moss.

The actual cost of AI investment for most companies is relatively small compared to total compensation expense, she added.

According to BCG's 2026 AI Radar, a survey of 2,360 global companies that was released in January, companies only expect to spend about 1.7% of revenue on AI in 2026.

Jan-Emmanuel De Neve, an economist and director of Oxford University's Wellbeing Research Center, told Business Insider he expects more companies to make similar trade-offs as they pursue AI, saying it is indicative of a "short-term mindset."

"When leaders openly cut human compensation to fund AI, they are trying to project decisive, tech-forward management. However, the actual message traveling to the workforce is that they do not have a secure future in the organization," De Neve said.

Employees are losing powerCuts to benefits and salary adjustments sit at the gentler end of the spectrum. Others have tied AI adoption to layoffs and fewer hiring opportunities.

Meta, for example, laid off 10% of its workforce in May, a move it linked to a push for efficiency and the need to fund investments.

Meta's stock price has surged in recent years, and in January, the company said its capital spending for the year would range from $115 billion to $135 billion.

Other firms, including Snap, Cisco, and Salesforce, have also announced staff cuts, citing AI efficiencies as a rationale; and Uber CEO Dara Khosrowshahi said in May that he'll cover the cost of increasing AI investment by hiring fewer people.

Teradata's head count has fallen by over 21% since December 2023, a drop of 1,400 people that the company said was made to support its growth strategy, company filings show.

Ellen Raim, an employment attorney with 30 years of corporate HR leadership experience, told Business Insider that many companies are leaner and under increasing organizational pressure to show productivity gains and stronger head count ROI.

"AI is being positioned as a way to do that quickly," she said.

Bill Winters used the phrase "lower-value human capital" to refer to employees he was planning to lay off.  Bloomberg/Getty Images Many workers have struggled with a perception that AI could lead to their well-being being sidelined, something recently reinforced when Standard Chartered CEO Bill Winters described some roles as "lower value, human capital." Winters later apologized. Alongside the growing tide of layoffs and examples of AI-focused compensation cuts at TTEC and Teradata, the power balance is shifting against workers as companies prioritize their AI futures.

Comments like Winters' reflect a broader trend of executives talking about people primarily as costs or capacity, Raim said. "That may make sense on a spreadsheet, but it can be corrosive inside an organization."

The risk, Raim said, is that companies underinvest in employees and undermine trust, at the very time they ask them to embrace these new tools and help figure out where AI can meaningfully improve the business.

Read next

Polly Thompson You're currently following this author! Want to unfollow? Unsubscribe via the link in your email.

Exclusive AI

Richard J. Petley, Chief Revenue Officer of Teradata (TDC 0.43%), reported the sale of 17,227 shares of common stock in open-market transactions on June 1, 2026, as disclosed in an SEC Form 4 filing.

Transaction summaryMetricValueShares sold (direct)17,227Transaction value~$603,000Post-transaction shares (direct)188,571Post-transaction value (direct ownership)~$6.95 millionTransaction value based on SEC Form 4 weighted average purchase price ($35.00); post-transaction value based on June 1, 2026 market close ($36.83).

Key questionsHow does this sale compare to Petley's recent trading activity?
Since May of this year, Petley has executed two open-market sales totaling 51,544 shares, with the current transaction reflecting a decrease in trade size that is consistent with the reduction in his available share inventory.What proportion of Petley's direct holdings was affected by this transaction?
The sale accounted for 8.4% of his direct ownership, moving his direct holdings from 205,798 shares to 188,571 shares.Were any indirect holdings or derivative securities involved?
The transaction exclusively involved direct ownership; no indirect entities or derivative securities, such as options, were part of the reported sale.What are the implications for Petley's ongoing ownership and selling capacity?
Following this sale, Petley retains a direct stake valued at approximately ~$6.95 million as of June 1, 2026, with remaining capacity for future transactions now limited by a lower share count.Company overviewMetricValuePrice (as of market close 2026-06-01)$36.83Revenue (TTM)$1.69 billionNet income (TTM)$421.00 million1-year price change52.01%* 1-year performance calculated using June 1st, 2026 as the reference date.

Company snapshotTeradata Vantage is the core product, providing a multi-cloud data analytics platform; services include consulting, support, and maintenance.The company generates revenue through software subscriptions, cloud-based analytics solutions, and professional services aimed at enterprise clients.Primary customers include organizations in financial services, government, healthcare, manufacturing, retail, telecommunications, and transportation sectors globally.Teradata operates at scale as a leading provider of enterprise analytics platforms, serving a diverse global client base. The company's strategy centers on enabling organizations to manage and analyze complex data across multi-cloud environments, supporting digital transformation and ecosystem simplification.

With a focus on mission-critical analytics and robust consulting services, Teradata maintains a competitive edge in the evolving data infrastructure market.

What this transaction means for investorsThe June 1 sale of Teradata stock by Chief Revenue Officer Richard Petley came at a time when shares experienced a rising price in 2026. The stock reached a 52-week high of $41.78 in February, and was still well above the low of $19.83 when Petley executed his sale.

That said, his transaction is not necessarily a cause for investor concern, given its non-discretionary nature. The disposition was implemented as part of a prearranged Rule 10b5-1 trading plan, adopted in December of 2025. Such plans are often implemented by insiders to avoid accusations of trading based on insider information.

Moreover, Petley retained over 188,000 shares post-transaction, indicating his equity stake remains robust. Holding on to the stock looks like a good strategy given Teradata’s business is performing well.

The rise of artificial intelligence created increased demand for the company’s data capabilities. This contributed to first-quarter sales of $444 million, up 6% from the previous year’s $418 million. Moreover, its recurring revenue of $400 million represented a 12% year-over-year increase, and bodes well for Teradata’s ability to maintain sales.

Key Takeaways Sempra reported Q1 adjusted EPS of $1.51, up 4.9% year over year.SRE's infrastructure segment earnings climbed to $262 million from $146 million a year ago.Sempra reaffirmed 2026 EPS guidance and projected 7-9% long-term EPS growth. Sempra (SRE - Free Report) reported first-quarter 2026 adjusted earnings per share (EPS) of $1.51, in line with the Zacks Consensus Estimate. The bottom line increased 4.9% from the year-ago quarter’s figure of $1.44.

Including one-time items, the company generated GAAP earnings of $1.58 per share compared with $1.39 in the first quarter of 2025.

SRE’s Total RevenuesRevenues of $3.66 billion missed the Zacks Consensus Estimate of $4.15 billion by 11.8%. The top line decreased 3.9% from $3.8 billion in the year-ago quarter.

SRE’s Segmental UpdateSempra California: Quarterly earnings amounted to $720 million compared with the year-ago quarter’s level of $724 million.

Sempra Texas Utilities: Earnings in this segment increased to $171 million from $146 million in the year-ago quarter.

Sempra Infrastructure: The segment recorded earnings of $262 million compared with $146 million in the year-ago quarter.

Parent and Other: The segment reported a loss of $116 million, wider than the prior-year period’s loss of $110 million.

SRE’s Financial UpdateAs of March 31, 2026, Sempra Energy’s cash and cash equivalents totaled $0.79 billion compared with $0.03 billion as of Dec. 31, 2025.

As of the same date, long-term debt and finance leases amounted to $30.85 billion compared with $28.98 billion as of Dec. 31, 2025.

Cash flow from operating activities in the first three months of 2026 totaled $1.81 billion compared with $1.48 billion a year ago.

SRE’s GuidanceThe company expects its 2026 adjusted earnings to be in the range of $4.80-$5.30 per share. The Zacks Consensus Estimate for 2026 earnings is pegged at $5.16 per share, higher than the midpoint of the company’s guided range.

SRE has also provided a full-year 2027 EPS guidance of $5.10-$5.70. Sempra expects a 7-9% long???term EPS growth rate.

SRE’s Zacks RankSempra Energy currently carries a Zacks Rank #3 (Hold). You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here.

Recent Releases TotalEnergies SE (TTE - Free Report) reported first-quarter 2026 operating earnings of $2.45 (€2.10) per share, which surpassed the Zacks Consensus Estimate of $1.99 by 23.1%. The bottom line improved 34% from the year-ago figure of $1.83 (€1.74).

TTE’s total revenues for the first quarter were $49.51 billion, which increased from the year-ago reported figure of $47.9 billion by 3.36%. The metric beat the Zacks Consensus Estimate of $46.85 billion by 5.9%.

Occidental Petroleum Corporation (OXY - Free Report) reported first-quarter 2026 operating earnings of $1.06 per share, which beat the Zacks Consensus Estimate of 65 cents by 63.08%. The bottom line also increased 21.8% from 87 cents in the year-ago quarter.

OXY’s total revenues were $5.11 billion, which missed the Zacks Consensus Estimate of $5.5 billion by 7%. The top line declined 25.3% year over year.

Devon Energy Corp. (DVN - Free Report) reported first-quarter 2026 EPS of $1.04, surpassing the Zacks Consensus Estimate of $1 by 4%. The metric was down 14% year over year.

DVN’s total revenues for the quarter were $3.80 billion, which lagged the Zacks Consensus Estimate of $4.16 billion by 8.5%. The top line decreased 14.5% from the year-ago quarter’s figure.

A $31.00 per share cash payment represents a premium of more than 20% over the recent market prices, estimated fair value, and par value of the shares 

, /PRNewswire/ -- Southern California Gas Company (SoCalGas) (OTCQB: SOCGP) (OTC PINK: SOCGM), a subsidiary of Sempra (NYSE: SRE), today announced it will hold a Special Meeting of Shareholders (the "Special Meeting") on July 13, 2026. The anticipated record date for the Special Meeting is May 18, 2026, and only shareholders at the close of business on that date will be eligible to vote.

At the Special Meeting, SoCalGas will seek approval from holders of its 6% Preferred Stock, par value $25.00, and 6% Preferred Stock, Series A, par value $25.00, to retire all outstanding shares of preferred stock in exchange for a cash payment of $31.00 per share, plus accrued and unpaid dividends to but excluding the retirement date. The cash payment represents a premium of more than 20% over the recent market prices, estimated fair value, and par value of the shares.

As part of our ongoing efforts to modernize our business and serve our stakeholders, SoCalGas is pursuing the proposed transaction to simplify its capital structure while delivering immediate value to shareholders. SoCalGas has filed a preliminary proxy statement for the Special Meeting with the U.S. Securities and Exchange Commission ("SEC") and, subject to the timing of SEC review, expects to file its definitive proxy statement on or about May 19, 2026, at which time shareholders as of the record date for the Special Meeting will be able to submit their votes.

SoCalGas urges all preferred shareholders to vote "FOR" this proposal in advance of the meeting. Copies of the proxy materials are available on SoCalGas' website at socalgas.com/about-us/special-shareholder-meeting. 

Shareholders with questions about how to vote should contact the Proxy Information Administrator for the Special Meeting:

D.F. King & Co, Inc.
28 Liberty Street, 53rd Floor
New York, New York 10005
Shareholders may call toll free: (800) 769-7666
Banks and brokers may call collect: (212) 914-0093
[email protected]

About SoCalGas
SoCalGas is the largest gas distribution utility in the United States, serving more than 21 million consumers across approximately 24,000 square miles of Central and Southern California. Our mission is: Safe, Reliable, and Affordable energy delivery today. Ready for tomorrow. SoCalGas is a recognized leader in the energy industry and has been named Corporate Member of the Year by the Los Angeles Chamber of Commerce for its volunteer leadership in the communities it serves. SoCalGas is a subsidiary of Sempra (NYSE: SRE), a leading U.S. utility holding company. For more information, visit SoCalGas.com/newsroom or connect with SoCalGas on social media @SoCalGas. 

Message Funded by Shareholders.

Additional Information about the Special Meeting and Where to Find It

In connection with the Special Meeting, on May 4, 2026, SoCalGas filed a preliminary proxy statement with the SEC. On or around May 19, 2026, SoCalGas expects to file its definitive proxy statement and mail proxy cards for the Special Meeting to the shareholders of SoCalGas entitled to vote at the Special Meeting. This communication is not intended to be, and is not, a substitute for the proxy statement or any other document that SoCalGas may file with the SEC in connection with the Special Meeting. SOCALGAS URGES INVESTORS TO READ THE PROXY STATEMENT AND OTHER MATERIALS FILED WITH THE SEC (INCLUDING ANY AMENDMENTS OR SUPPLEMENTS THERETO) CAREFULLY AND IN THEIR ENTIRETY AS THEY BECOME AVAILABLE BECAUSE THEY CONTAIN OR WILL CONTAIN IMPORTANT INFORMATION ABOUT THE SPECIAL MEETING AND THE PROPOSALS TO BE VOTED ON AT THE SPECIAL MEETING. Investors are able to obtain free copies of the proxy statement and other documents that will be filed by SoCalGas with the SEC (when available) at http://www.sec.gov, the SEC's website, or from SoCalGas' website at https://www.socalgas.com/about-us/special-shareholder-meeting. In addition, investors can obtain the Notice of Special Meeting of Shareholders, proxy statement and proxy card free of charge (when available) at www.proxyvote.com.

This communication does not constitute a solicitation of proxy, an offer to purchase or a solicitation of an offer to sell any securities. SoCalGas, its directors and certain of its officers and employees may be deemed to be participants in the solicitation of proxies from shareholders in connection with the Special Meeting. Information about SoCalGas' directors and executive officers is set forth in its definitive information statement for its 2026 annual shareholders meeting filed with the SEC on April 14, 2026. These documents may be obtained free of charge at the SEC's website at www.sec.gov or from the Sempra website at www.sempra.com under the "Investors" and "SEC Filings" tabs. Additional information regarding the interests of participants in the solicitation of proxies in connection with the Special Meetings will be included in the definitive proxy statement that SoCalGas will file the SEC in connection with the Special Meeting and other relevant materials SoCalGas may file with the SEC.

Information Regarding Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are based on assumptions about the future, involve risks and uncertainties, and are not guarantees. Future results may differ materially from those expressed or implied in any forward-looking statement. These forward-looking statements represent our estimates and assumptions only as of the date of this press release. We assume no obligation to update or revise any forward-looking statement as a result of new information, future events or otherwise.

In this press release, forward-looking statements can be identified by words such as "believe," "expect," "intend," "anticipate," "contemplate," "plan," "estimate," "project," "forecast," "envision," "should," "could," "would," "will," "confident," "may," "can," "potential," "possible," "proposed," "in process," "construct," "develop," "opportunity," "preliminary," "pro forma," "strategic," "initiative," "target," "outlook," "optimistic," "poised," "positioned," "maintain," "continue," "progress," "advance," "goal," "aim," "commit," or similar expressions, or when we discuss our guidance, priorities, strategies, goals, vision, mission, projections, intentions or expectations.

Factors, among others, that could cause actual results and events to differ materially from those expressed or implied in any forward-looking statement include: the ability to obtain all necessary approvals to effect the amendment of our restated articles of incorporation and the retirement of the preferred stock; the ability to achieve the anticipated benefits of the transactions described herein; the effects on such transactions of industry, market, economic, political or regulatory conditions outside of SoCalGas' control; fees, costs and expenses associated with the transactions described herein; transaction-related tax and accounting impacts; the diversion of management time on transaction-related issues; and the effects on such transactions of factors affecting SoCalGas' business and securities, including the risks and uncertainties discussed in the reports we file with the SEC, including under the headings "Risk Factors" and "Information Regarding Forward-Looking Statements" in our annual report on Form 10-K for the year ended December 31, 2025 and subsequently filed quarterly reports on Form 10-Q. Investors should not rely unduly on any forward-looking statements.

SOURCE Southern California Gas Company